Literature DB >> 16491283

A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.

Robert Lindsay1, Felicia Cosman, Hua Zhou, Mathias P Bostrom, Victor W Shen, JoAnn D Cruz, Jeri W Nieves, David W Dempster.   

Abstract

UNLABELLED: We describe a quadruple tetracycline labeling method that allows longitudinal assessment of short-term changes in bone formation in a single biopsy. We show that 1 month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation.
INTRODUCTION: Iliac crest biopsy, with histomorphometric evaluation, provides important information about cellular activity in bone. However, to obtain longitudinal information, repeat biopsies must be performed. In this study, we show the capability to obtain short-term longitudinal information on bone formation in a single biopsy using a novel, quadruple labeling technique.
MATERIALS AND METHODS: Two tetracycline labels were administered using a standard 3 days on, 12 days off, 3 days on format. Four weeks later, the tetracycline labeling was repeated using the same schedule but with a different tetracycline that can be distinguished from the first by its color under fluorescent light. Iliac crest biopsies were performed 1 week later and prepared undecalcified for histomorphometry. Indices of bone formation 1 month apart were measured and calculated using the two sets of labels. We used this method to investigate the early effects of teriparatide [hPTH(1-34)] treatment on bone formation. The results were compared with those from a group of control subjects who were quadruple-labeled, but did not receive hPTH(1-34).
RESULTS: Treatment with hPTH(1-34) dramatically stimulated bone formation on cancellous and endocortical surfaces. This was achieved by both an increase in the linear rate of matrix apposition and extension of the bone-forming surface. New bone was deposited on previously quiescent surfaces (i.e., modeling-based formation), but a proportion of this could occur by encroachment from adjacent resorption cavities.
CONCLUSIONS: A single transiliac crest bone biopsy, after sequential administration of two sets of tetracycline labels is a useful approach to study the short-term effects of anabolic agents on human bone. One month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16491283     DOI: 10.1359/JBMR.051109

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  85 in total

Review 1.  T cells: critical bone regulators in health and disease.

Authors:  Roberto Pacifici
Journal:  Bone       Date:  2010-05-07       Impact factor: 4.398

2.  Characterization of eight different tetracyclines: advances in fluorescence bone labeling.

Authors:  Christoph Pautke; Stephan Vogt; Kilian Kreutzer; Cornelia Haczek; Gabriele Wexel; Andreas Kolk; Andreas B Imhoff; Horst Zitzelsberger; Stefan Milz; Thomas Tischer
Journal:  J Anat       Date:  2010-04-26       Impact factor: 2.610

3.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

Review 4.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

5.  Long-term clinical study and multiscale analysis of in vivo biodegradation mechanism of Mg alloy.

Authors:  Jee-Wook Lee; Hyung-Seop Han; Kyeong-Jin Han; Jimin Park; Hojeong Jeon; Myoung-Ryul Ok; Hyun-Kwang Seok; Jae-Pyoung Ahn; Kyung Eun Lee; Dong-Ho Lee; Seok-Jo Yang; Sung-Youn Cho; Pil-Ryung Cha; Hoon Kwon; Tae-Hyun Nam; Jee Hye Lo Han; Hyoung-Jin Rho; Kang-Sik Lee; Yu-Chan Kim; Diego Mantovani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 6.  Current Status of Bone-Forming Therapies for the Management of Osteoporosis.

Authors:  Anne Sophie Koldkjær Sølling; Torben Harsløf; Bente Langdahl
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 7.  Parathyroid hormone analogues in the treatment of osteoporosis.

Authors:  Marius E Kraenzlin; Christian Meier
Journal:  Nat Rev Endocrinol       Date:  2011-07-12       Impact factor: 43.330

Review 8.  Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis.

Authors:  T J Martin; N A Sims; K W Ng
Journal:  Osteoporos Int       Date:  2008-03-13       Impact factor: 4.507

Review 9.  Normal bone anatomy and physiology.

Authors:  Bart Clarke
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw.

Authors:  K M Kim; W Park; S Y Oh; H-J Kim; W Nam; S-K Lim; Y Rhee; I H Cha
Journal:  Osteoporos Int       Date:  2014-02-20       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.